Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 55NETWORK 10NIH 4INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 196Neoplasms 104Colorectal Neoplasms 91Stomach Neoplasms 80Uterine Cervical Neoplasms 71Carcinoma, Non-Small-Cell Lung 67Carcinoma, Hepatocellular 54Prostatic Neoplasms 48Lung Neoplasms 48Rectal Neoplasms 46Esophageal Neoplasms 39Pancreatic Neoplasms 37Colonic Neoplasms 36Ovarian Neoplasms 35Recurrence 33Head and Neck Neoplasms 33Neoplasm Metastasis 28Motor Activity 28Multiple Myeloma 27Small Cell Lung Carcinoma 26Melanoma 25Polycystic Ovary Syndrome 24Lymphoma, Non-Hodgkin 24Lymphoma 24Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Pain 20Brain Neoplasms 20Nasopharyngeal Carcinoma 18Hematologic Neoplasms 17

Interventions

eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Neurotoxicity Syndromes × Clear all
NCT02864030 2021-03-04

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Oncologia Medica dell'Ospedale Fatebenefratelli

Phase 4 Completed
200 enrolled
Breast

Breast Neoplasms, Neurotoxicity Syndromes, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡